Older patients benefit from XELOX after surgery

Update from 2010 GI Cancers Symposium Colon cancer patients over 70 actually had a greater reduction in disease-free survival than did younger ones with a new regimen of Xeloda® and oxaliplatin compared to older IV 5-FU treatments according to a new analysis reported at the GI Cancers Symposium in Orlando. With the bolus IV 5-FU and…  Read More

XELOX Beats 5-FU with Fewer Recurrences

A combination of Xeloda and Eloxatin (XELOX) was better than standard 5-FU and leucovorin chemotherapy in reducing recurrences of stage III colon cancer after surgery.  Significantly more patients receiving XELOX were alive without cancer three years after treatment began. Roche announced results of a Phase III clinical trial that compared XELOX chemotherapy to bolus 5-FU and…  Read More

Comparing 5-FU or Capecitabine Combined with Oxaliplatin

Infusional 5-FU or oral Xeloda® (capecitabine) are two different drugs that can be combined with Eloxatin® (oxaliplatin) to treat colorectal cancer that has spread.  Six different randomized clinical trials have compared the two approaches. Researchers analyzed a pool of all six trials to find out if one approach is better than the other. While they found…  Read More

Switching from 5FU to Xeloda Can Cause Significant Side Effects

An immediate switch from 5-FU treatment to Xeloda® (capecitabine) for stage III colon cancer caused so much toxicity that a trial designed to test patient preferences for treatment had to be stopped. Patients in the Patient Preference in Adjuvant Therapy (PACT) trial who switched after 6 weeks from weekly 5-FU with leucovorin to oral capecitabine experienced…  Read More